Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (551-560 of 692) with videos related to

Pageof 70
Sort By:
Psychological Medicine|March 17, 2016
Development of a stage-dependent prognostic model to predict psychosis in ultra-high-risk patients seeking treatment for co-morbid psychiatric disordersH K Ising, S Ruhrmann, N A F M Burger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 31, 2023
Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung CancerSimon P de Leeuw, Melinda A Pruis, Barend J Sikkema, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2011
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancerE F Smit, M A Socinski, B P Mullaney, et al.
Plos One|August 31, 2017
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progressionA J van der Wekken, J L Kuiper, A Saber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021
Study of <sup>89</sup>Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung CancerAnna-Larissa N Niemeijer, Daniela E Oprea-Lager, Marc C Huisman, et al.
Nature Reviews. Clinical Oncology|March 15, 2025
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trialsSophie M Ernst, Mihaela Aldea, Jan H von der Thüsen, et al.
Anticancer Research|November 2, 2010
Weekly chemoradiation (docetaxel/cisplatin) followed by surgery in stage III NSCLC; a multicentre phase II studyKlaartje W Maas, Sherif Y El Sharouni, Erik C J Phernambucq, et al.
Lung Cancer (Amsterdam, Netherlands)|February 18, 2014
EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?L E L Hendriks, E F Smit, B A H Vosse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2023
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 InsertionsZofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancerMark A Socinski, Egbert F Smit, Paul Lorigan, et al.
Pageof 70

Showing results (551-560 of 692) with videos related to

Sort By:
Pageof 70
Psychological Medicine|March 17, 2016
Development of a stage-dependent prognostic model to predict psychosis in ultra-high-risk patients seeking treatment for co-morbid psychiatric disordersH K Ising, S Ruhrmann, N A F M Burger, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 31, 2023
Analysis of Serious Weight Gain in Patients Using Alectinib for ALK-Positive Lung CancerSimon P de Leeuw, Melinda A Pruis, Barend J Sikkema, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 22, 2011
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancerE F Smit, M A Socinski, B P Mullaney, et al.
Plos One|August 31, 2017
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progressionA J van der Wekken, J L Kuiper, A Saber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 17, 2021
Study of <sup>89</sup>Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non-Small Cell Lung CancerAnna-Larissa N Niemeijer, Daniela E Oprea-Lager, Marc C Huisman, et al.
Nature Reviews. Clinical Oncology|March 15, 2025
Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trialsSophie M Ernst, Mihaela Aldea, Jan H von der Thüsen, et al.
Anticancer Research|November 2, 2010
Weekly chemoradiation (docetaxel/cisplatin) followed by surgery in stage III NSCLC; a multicentre phase II studyKlaartje W Maas, Sherif Y El Sharouni, Erik C J Phernambucq, et al.
Lung Cancer (Amsterdam, Netherlands)|February 18, 2014
EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?L E L Hendriks, E F Smit, B A H Vosse, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2023
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 InsertionsZofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2009
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancerMark A Socinski, Egbert F Smit, Paul Lorigan, et al.
Pageof 70